Safety and efficacy outcomes of the Xen45 Gel Stent use for refractory glaucoma: a surgery series from surgeon trainees at a tertiary teaching hospital

Table 1 Baseline Demographics and Characteristics

Demographic/Characteristic	n = 28 subjects
Mean Age, years (SD)	66.6 (11.0)
Female, n (%)	11 (39.3)
Ethnicity, n (%)
Non-Hispanic White	13 (46.0)
Black/African American	15 (54.0)
Type of glaucoma, n (%)
Primary Open Angle	17 (60.7)
Juvenile Open Angle	4 (14.3)
Normal Tension	3 (10.7)
Pseudoexfoliative	2 (7.1)
Uveitic	2 (7.1)
Preoperative lens status, n (%)
phakic	20 (71.4)
pseudophakic	8 (28.6)
Total Prior Glaucoma Surgery, n (%)^a	6 (21.4%)
Non-valved tube	2 (7.1)
ExPRESS shunt with MMC	2 (7.1)
Ahmed	1 (3.6)
TM iStent	1 (3.6)
Trabeculectomy	1 (3.6)
Diode	1 (3.6)
Goniotomy (GATT or KDB)	0 (0.0)
Total Prior Non-Glaucoma Ocular Procedures, n (%)	23 (82.1)
Laser Trabeculoplasty	21 (75.0)
Prior other non-phacoemulsification surgery ^b	2 (7.1)
Glaucoma Severity^c
Severe	22 (78.6)
Moderate	2 (7.14)
Mild	4 (14.3)
Mean Deviation, dB (SD)	−14.58 (9.0)
Mean preoperative IOP, mmHg (range, SD)	21.7 (5.6)
IOP range mmHg	12–34
Mean Glaucoma Medication Classes^d, n (SD)	3.7 (0.8)
1 class	0 (0.0)
2 classes	2 (7.1)
3 classes	7 (25.0)
4 classes	16 (57.1)
5 classes	3 (10.7)

SD= standard deviation; MMC= mitomycin C; IOP= intraocular pressure; GATT= gonioscopy-assisted transluminal trabeculotomy; KDB= Kahook Dual Blade
^aOne subject with 3 prior glaucoma surgeries: a non-valved tube, diode, and ExPRESS shunt with MMC
^bIOL repositioning (n = 1), pars plana vitrectomy (n = 1)
^cGlaucoma severity is described as optic nerve abnormalities consistent with glaucoma and the following categorization of glaucomatous visual field abnormalities: Severe = both hemifields and/or loss within 5 degrees of fixation in at least one hemifield, Moderate = glaucomatous visual field abnormalities in one hemifield and not within 5 degrees of fixation, Mild = no abnormalities or only present on short-wavelength automated perimetry or frequency doubling perimetry
^dOral carbonic anhydrase inhibitors are considered their own class

ISSN: 2326-0254